Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection

Rabbit anti-thymocyte globulin (rATG) is currently the treatment of choice for glucocorticoid-resistant, recurrent, or severe acute allograft rejection (AR). However, rATG is associated with severe infusion-related side effects. Alemtuzumab is incidentally given to kidney transplant recipients as tr...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Zwan, Marieke, Clahsen-Van Groningen, Marian C., van den Hoogen, Martijn W. F., Kho, Marcia M. L., Roodnat, Joke I., Mauff, Katya A. L., Roelen, Dave L., van Agteren, Madelon, Baan, Carla C., Hesselink, Dennis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350932/
https://www.ncbi.nlm.nih.gov/pubmed/32719676
http://dx.doi.org/10.3389/fimmu.2020.01332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350932/
https://www.ncbi.nlm.nih.gov/pubmed/32719676
http://dx.doi.org/10.3389/fimmu.2020.01332

Ejemplares similares